Problem decomposition
A public Cathedral work ladder for community and expert contributions to artemisinin-resistance research.
Problem statement
Break artemisinin-resistant malaria in East Africa into concrete work packages across literature review, field data, molecular structure, population genetics, and treatment strategy.
Claim flow
4 claims
Claim 1
root
K13 mutations alter parasite survival under artemisinin pressure
Claim 2
1 deps
Regional spread differs across East African countries
Claim 3
1 deps
Treatment patterns and parasite fitness both shape hotspot emergence
Claim 4
1 deps
Existing combination regimens may suppress resistant lineages
Collect public reports from clinics, WHO updates, and local health notes. Tag country, district, date, treatment regimen, and whether K13 genotype is reported.
Current knowledge
Anyone can help turn scattered field reports into structured observations.
Produce short Swahili and English summaries explaining what resistance is, what it is not, and why completing ACT treatment matters.
Current knowledge
Public understanding affects treatment adherence and surveillance quality.
Search PubMed, Semantic Scholar, and Crossref for K13/C580Y studies in Uganda, Tanzania, Rwanda, and Ethiopia. Extract year, sample size, mutations, clearance phenotype, and location.
Current knowledge
The literature exists but is fragmented across clinical, genomic, and surveillance papers.
Create an evidence matrix separating delayed parasite clearance, treatment failure, K13 genotype, and ACT partner-drug failure.
Current knowledge
Resistance is often confused with treatment failure; definitions drive policy.
Use AlphaFold DB for wildtype and ESMFold for mutants. Compare mutation sites, structural confidence, and candidate interaction surfaces.
Current knowledge
The structural reason for C580Y dominance remains unresolved.
Link K13 prevalence data to country, year, and lineage where available. Identify whether spread is imported, locally selected, or both.
Current knowledge
East African spread may combine local emergence with cross-border movement.
Prioritize existing drug combinations that could suppress K13-mediated partial resistance without waiting for new compounds.
Current knowledge
Policy needs shorter timelines than new drug discovery can provide.
Specify experiments that distinguish reduced artemisinin activation, altered endocytosis, stress response survival, and fitness-cost models.
Current knowledge
Multiple mechanistic explanations remain compatible with current evidence.